BMS-8

BMS-8

• CAS Number: 1675201-90-7
• UNSPSC Description: BMS-8 inhibits the PD-1/PD-L1 interaction with IC50 of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1[1].
• Target Antigen: PD-1/PD-L1
• Type: Reference compound
• Related Pathways: Immunology/Inflammation
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/bms-8.html
• Purity: 98.0
• Solubility: DMSO : 83.33 mg/mL (ultrasonic)
• Smiles: CC1=C(C=CC=C1C2=CC=CC=C2)COC3=CC=C(C=C3Br)CN4CCCCC4C(O)=O
• Molecular Weight: 494.42
• References & Citations: [1]Eun-Hye Kim, et al. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions. Int J Mol Sci. 2020 May 21;21(10):3639.|[2]Danfeng Shi, et al. Computational Insight Into the Small Molecule Intervening PD-L1 Dimerization and the Potential Structure-Activity Relationship. Front Chem. 2019 Nov 12;7:764.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, protect from light)
• Clinical Information: No Development Reported